Compare Enveric Biosciences Inc (ENVB) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Newmont Corporation — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Newmont Corporation trades at $118.01 (market cap $121.75B). The key difference: Newmont Corporation is far larger — about 17904.4× Enveric Biosciences Inc's market cap, and Newmont Corporation pays a 0.9% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Newmont Corporation for 58 Days on average.
| ENVB | NEM | |
|---|---|---|
Market Cap | $6.80M | $121.75B |
Volume | 64,867 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $135.14 |
52-Week Low | $1.27 | $78.63 |
Typical Hold Time | 14 Days | 58 Days |
Enterprise Value | -$1.49M | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Newmont (NEM) trades at $118.23, up 4.13% today, supported by strong earnings beats and record free cash flow. The stock shows a bearish technical signal near key support at $114, while fundamentals are robust with a P/E of 14.57, net income margin of 33.36%, and revenue growth to $22.67B in 2025. Analyst consensus is strongly bullish with a $136.83 price target.
The outlook for NEM is positive, driven by operational improvements and a constructive gold market. Key risks include gold price volatility and execution of growth projects. With no analyst sell ratings and strong institutional interest, the stock presents a compelling opportunity for investors seeking exposure to a leading gold producer.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
